C
Constructive Bio
Biotech & Life Sciences · Cambridge, United Kingdom · Founded 2021
Realising the potential of genome rewriting to drive the next generation of bioprocesses and biopharmaceuticals MoreLess
Constructive Bio is a UK-based biotechnology company focused on re-engineering biology by creating synthetic genomes from scratch.
The company's core technology involves rewriting and reprogramming the genetic code of bacterial strains. By hijacking the cell's protein translation machinery, they can synthesize novel biopolymers and programmable biomolecules with high fidelity and scalability.
This capability allows for the creation of new classes of enzymes, pharmaceuticals, and biomaterials, targeting the drug discovery and biomanufacturing sectors.
The company operates on a B2B model, providing its technology for various commercial applications. Constructive Bio has secured significant venture funding, including a $15 million seed round and a $58 million Series A financing, to advance its genome synthesis platform.
Keywords: synthetic biology, genome synthesis, genetic code reprogramming, biomolecules, biopolymers, drug discovery, biomanufacturing, protein translation, enzymes, pharmaceuticals
Company overview
Constructive Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United Kingdom
- Employees
- 69
- Open positions
- 6
- Dealroom signal
- 92.8
Valuation & funding
Constructive Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Mar 2026 | $20M | $284M | Undisclosed | ↗ |
| EARLY VCOther financing | Apr 2025 | $0 | — | LongeVC | ↗ |
| GRANTOther financing | Feb 2025 | $749K | — | UK Research and Innovation | — |
| SERIES AOther financing | Sep 2024 | $58M | $232M | Jonathan Milner · Ahren Innovation Capital · OMX Ventures · +ND Capital | ↗ |
| SEEDOther financing | Aug 2022 | $17M | $66M | General Inception · Ahren Innovation Capital · Amadeus Capital Partners · OMX Ventures | ↗ |
| SPINOUTOther financing | Nov 2021 | MRC Laboratory of Molecular Biology · University of Cambridge | ↗ |
Growth signals
Constructive Bio website traffic
Latest recorded traffic for Constructive Bio is 7K monthly website visits, up 52.2% over the last three months. Constructive Bio's team grew 16.9% over the past year.
Hiring
Open positions at Constructive Bio
Current openings linked to this company in Dealroom.
Comparisons
Constructive Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Constructive Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Constructive Bio has talent and traffic
team presence
In the news
Latest news about Constructive Bio
Recent press, funding announcements, and product moves mentioning Constructive Bio — open to read from the original sources.
Market sentiment
What the market is saying about Constructive Bio
An AI-synthesized read of the highest-engagement posts about Constructive Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Constructive Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.